BIOMAT Database Logo BIOMAT Database Logo

Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. 1997

P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.

Some of the issues associated with standardizing the diagnosis of dementia in clinical trials are outlined. Deliberations of the Working Group on Diagnostic Criteria and their recommendations for future actions needed to develop a consensus are described.

UI MeSH Term Description Entries
D007391 International Cooperation The interaction of persons or groups of persons representing various nations in the pursuit of a common goal or interest. Foreign Aid,Treaties,Aid, Foreign,Cooperation, International,Treaty
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015577 Geriatric Assessment Evaluation of the level of physical, physiological, or mental functioning in the older population group. Assessment, Geriatric,Assessments, Geriatric,Geriatric Assessments
D017410 Practice Guidelines as Topic Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. Clinical Guidelines as Topic,Best Practices,Best Practice
D018697 Nootropic Agents Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. Anti-Dementia Agent,Antidementia Agent,Cognitive Enhancer,Cognitive Enhancers,Nootropic,Nootropic Agent,Nootropic Drug,Procognitive Agent,Anti-Dementia Agents,Antidementia Agents,Nootropic Drugs,Nootropics,Procognitive Agents,Agent, Anti-Dementia,Agent, Antidementia,Agent, Nootropic,Agent, Procognitive,Agents, Anti-Dementia,Agents, Antidementia,Agents, Nootropic,Agents, Procognitive,Anti Dementia Agent,Anti Dementia Agents,Drug, Nootropic,Drugs, Nootropic,Enhancer, Cognitive,Enhancers, Cognitive

Related Publications

P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
length of clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
P Antuono, and R Doody, and S Gilman, and J Huff, and P Scheltens, and K Ueda, and Z S Khachaturian
Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
Copied contents to your clipboard!